The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | ELEVATE CLL TN & ASCEND: acalabrutinib in CLL
Toby Eyre, MD, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares an update on two randomized clinical trials of acalabrutinib in chronic lymphocytic leukemia (CLL). The ELEVATE CLL TN trial (NCT02475681) is investigating obinutuzumab plus chlorambucil versus acalabrutinib plus obinutuzumab or acalabrutinib monotherapy in patients with treatment-naïve CLL. The ASCEND trial (NCT02970318) is comparing acalabrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory CLL. Dr Eyre discusses the results of these trials, highlighting progression-free survival (PFS) benefits in the acalabrutinib arms and outlines the implications of these findings for clinical practice.
